# Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

> **NCT01242787** · PHASE2 · UNKNOWN · sponsor: **LG Life Sciences** · enrollment: 115 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** LB80380
- **DRUG:** Entecavir 0.5 mg

## Key facts

- **NCT ID:** NCT01242787
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-08
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242787, "Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01242787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*